{"id":"bevacizumab-eu","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04126044","NCT02031991","NCT02364999","NCT04325698"],"_pubmed":{"count":16,"papers":[{"date":"2025","pmid":"40795416","title":"Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.","authors":"Andric Z","journal":"Cancer treatment and research communications"},{"date":"2023","pmid":"38293674","title":"Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.","authors":"Park S","journal":"Frontiers in pharmacology"},{"date":"2023 Nov","pmid":"37935428","title":"Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.","authors":"Chen L","journal":"Cancer medicine"},{"date":"2023 Aug","pmid":"36595042","title":"Bevacizumab biosimilar candidate TAB008 compared to Avastin(®) in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study.","authors":"Lu S","journal":"Journal of cancer research and clinical oncology"},{"date":"2022 Nov","pmid":"36169807","title":"Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.","authors":"Verschraegen C","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"}]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:37:23.605972","offLabel":[],"timeline":[{"date":"2014","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTION) — Healthy"},{"date":"2017","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carbo) — Non-Small Cell Lung Cancer"}],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"Bevacizumab-EU is an antibody that inhibits vascular endothelial growth factor A, a protein involved in the formation of new blood vessels. It is used as a first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.","brandName":"Bevacizumab-EU","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we","explanation":"Bevacizumab works by targeting a specific protein called VEGF (vascular endothelial growth factor) that tumors produce to stimulate the growth of new blood vessels. Tumors need their own blood supply to grow beyond a certain size and to spread to other parts of the body. By binding to and neutralizing VEGF, bevacizumab prevents this new vessel formation, essentially starving the tumor of nutrients and oxygen.\n\nThis approach is different from traditional chemotherapy because it doesn't directly kill cancer cells. Instead, it cuts off the tumor's life support system. By limiting blood vessel growth around the cancer, bevacizumab can slow tumor progression and improve survival outcomes. The drug is given as an intravenous infusion, often in combination with chemotherapy or other cancer treatments.\n\nBecause bevacizumab targets a process that tumors depend on rather than attacking the cancer cells themselves, it can be effective across multiple cancer types where VEGF-driven angiogenesis (blood vessel formation) plays an important role. This mechanism also explains why bevacizumab must be used carefully, as blocking blood vessel formation can affect normal tissues and organs throughout the body.","oneSentence":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we","technicalDetail":""},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"bevacizumab-eu","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Advanced Non-squamous NSCLC","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"_fixedFields":["pubmed(16)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03676192","phase":"PHASE3","title":"To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-02-01","conditions":"Adenocarcinoma of Lung","enrollment":689,"completionDate":"2023-09-19","primaryEndpoint":"Objective Response Rate (ORR) During the Induction Study Period From Central Review"},{"nctId":"NCT06232902","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Tumor","enrollment":84,"completionDate":"2024-11-18","primaryEndpoint":"AUC0-∞"},{"nctId":"NCT03390673","phase":"PHASE1","title":"To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-09-19","conditions":"Healthy Volunteers","enrollment":119,"completionDate":"2019-03-13","primaryEndpoint":"Area under Curve (AUC, Pharmacokinetics)"},{"nctId":"NCT04325698","phase":"PHASE3","title":"A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-06-11","conditions":"Advanced Non-squamous NSCLC","enrollment":8,"completionDate":"2021-05-10","primaryEndpoint":"Percentage of Participants Achieving Objective Response"},{"nctId":"NCT04238663","phase":"PHASE1","title":"Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-09-24","conditions":"Healthy Volunteers","enrollment":115,"completionDate":"2020-03-17","primaryEndpoint":"Cmax: Maximum Observed Serum Concentration"},{"nctId":"NCT05427305","phase":"PHASE3","title":"TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2017-10-20","conditions":"Efficacy","enrollment":549,"completionDate":"2020-03-24","primaryEndpoint":"ORR"},{"nctId":"NCT02469987","phase":"PHASE1","title":"Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-04","conditions":"Healthy","enrollment":111,"completionDate":"2015-10","primaryEndpoint":"Area under the plasma concentration versus time curve (AUC) for bevacizumab."},{"nctId":"NCT03329911","phase":"PHASE3","title":"A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2017-10-20","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":651,"completionDate":"2021-05-27","primaryEndpoint":"Overall Response Rate"},{"nctId":"NCT04126044","phase":"PHASE1","title":"A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Pharmacokinetics","enrollment":0,"completionDate":"2021-07-10","primaryEndpoint":"AUC0-t (Area under the serum concentration-time profile from time 0 to last time point with quantifiable concentration)"},{"nctId":"NCT03296163","phase":"PHASE3","title":"A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2018-02-06","conditions":"Non-small Cell Lung Cancer","enrollment":627,"completionDate":"2020-02-27","primaryEndpoint":"Objective Response Rate (ORR) at Week 18"},{"nctId":"NCT03293654","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2017-12-07","conditions":"Healthy Volunteers","enrollment":114,"completionDate":"2019-05-29","primaryEndpoint":"Cmax: Maximum Observed Serum Concentration"},{"nctId":"NCT04238650","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-08-02","conditions":"Healthy Volunteers, Male, Japanese","enrollment":49,"completionDate":"2019-12-27","primaryEndpoint":"Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]"},{"nctId":"NCT03247673","phase":"PHASE1","title":"To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin","status":"COMPLETED","sponsor":"Celltrion","startDate":"2017-08-07","conditions":"Healthy","enrollment":141,"completionDate":"2018-01-17","primaryEndpoint":"AUC0-inf"},{"nctId":"NCT03576651","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"JHL Biotech, Inc.","startDate":"2018-03-24","conditions":"Healthy Male Subjects","enrollment":154,"completionDate":"2019-12-13","primaryEndpoint":"AUC0-inf"},{"nctId":"NCT01984242","phase":"PHASE2","title":"A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-08","conditions":"Renal Cell Carcinoma","enrollment":305,"completionDate":"2019-01-08","primaryEndpoint":"Percentage of Participants With Disease Progression Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Via Independent Review Committee (IRC) Assessment or Death in Intent-to-T"},{"nctId":"NCT02453672","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-04","conditions":"Healthy","enrollment":119,"completionDate":"2015-09","primaryEndpoint":"Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)"},{"nctId":"NCT02364999","phase":"PHASE3","title":"A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04","conditions":"Non-Small Cell Lung Cancer","enrollment":719,"completionDate":"2017-12","primaryEndpoint":"Objective Response Rate (ORR) by Week 19"},{"nctId":"NCT03030430","phase":"PHASE1","title":"Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2016-03-15","conditions":"NSCLC","enrollment":128,"completionDate":"2017-06-28","primaryEndpoint":"area under curve (AUC)0~∞"},{"nctId":"NCT03131700","phase":"PHASE1","title":"Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator","status":"WITHDRAWN","sponsor":"TRPHARM","startDate":"2017-12","conditions":"Healthy","enrollment":0,"completionDate":"2018-01","primaryEndpoint":"Maximum plasma concentration"},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127,"completionDate":"2016-11-04","primaryEndpoint":"Change in central subfield mean macular thickness as a measurement of efficacy"},{"nctId":"NCT02879097","phase":"PHASE3","title":"Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-12","conditions":"Non-Small Cell Lung Carcinoma","enrollment":200,"completionDate":"2018-05","primaryEndpoint":"Objective Response Rate (ORR)"},{"nctId":"NCT02031991","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Healthy","enrollment":102,"completionDate":"2014-08","primaryEndpoint":"Maximum Observed Plasma Concentration (Cmax)"},{"nctId":"NCT01859234","phase":"NA","title":"89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2013-05","conditions":"Multiple Myeloma","enrollment":20,"completionDate":"","primaryEndpoint":"Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T21:51:56.672708","crossReferences":{"chemblId":"CHEMBL1201583"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[{"date":"2025","pmid":"40795416","title":"Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.","journal":"Cancer treatment and research communications"},{"date":"2023","pmid":"38293674","title":"Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.","journal":"Frontiers in pharmacology"},{"date":"2023 Nov","pmid":"37935428","title":"Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.","journal":"Cancer medicine"},{"date":"2023 Aug","pmid":"36595042","title":"Bevacizumab biosimilar candidate TAB008 compared to Avastin(®) in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study.","journal":"Journal of cancer research and clinical oncology"},{"date":"2022 Nov","pmid":"36169807","title":"Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"}],"_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}